Tazemetostat Mesothelioma, What Can We Offer A Patient With A Malignant Mesothelioma Iaslc

The manufacturer of tazemetostat has now formally begun its planned phase 2 clinical trial of this novel targeted mesothelioma therapeutic.

Simmons beautyrest platinum phillipsburg iii. In part 1 12 subjects with relapsed or refractory malignant mesothelioma regardless of bap1 status will be treated and undergo pharmacokinetics pk blood sample collection after a single tazemetostat 800 mg. Standard of care treatment for mesothelioma typically involves a combination of chemotherapy surgery and radiation but the effectiveness has been limited. In part 1 12 patients with relapsed or refractory malignant mesothelioma regardless of bap1 status will be treated with a single dose of tazemetostat to assess its pharmacokinetics.

There is no cure for mesothelioma and patients typically survive only nine to 18 months after being diagnosed. According to lead investigator marjorie glass zauderer md ms facp memorial sloan kettering cancer center new york and colleagues preclinical data shave shown that inactivation of bap1. Tazemetostat is reported to be capable of inhibiting ezh2 activity.

Each patient in this trial received tazemetostat twice daily. Food and drug administration for the treatment of mesothelioma but its effectiveness is limited. Screening of subjects to determine eligibility for the study will be performed within 21 days of the first planned dose of tazemetostat.

A possible new drug for mesothelioma has received fda approval for the treatment of advanced epithelioid sarcoma. Chemotherapy with cisplatin and pemetrexed is approved by the us. It is a brand new kind of drug that blocks a protein called ezh2.

Less than one fourth of. Tazemetostat tazverik is an oral medication made by a company called epizyme. In a phase 2 study tazemetostat was well tolerated and demonstrated anti tumor activity in patients with bap1 deficient relapsed or refractory malignant mesothelioma j clin onco.

How tazemetostat works for mesothelioma treatment. Phase 2 trial data being presented at the virtual 2020 asco annual meeting demonstrate the antitumor activity of tazemetostat in patients with bap1 deficient relapsed or refractory malignant mesothelioma. Abstr 9058preclinical data showed that bap1 inactivation sensitizes mesothelial cells to inhibition of ezh2 wrote marjorie glass zauderer md memorial sloan kettering cancer center new.

Epizyme inc based in cambridge massachusetts announced in mid august 2016 that the first of an expected 67 patients began receiving tazemetostat. While the gene therapy didnt lead to a complete disease response it did help stop mesotheliomas growth in many cases. In part 2 patients with bap1 mutated relapsed or refractory malignant mesothelioma will receive oral tazemetostat twice daily until disease progression.